stoxline Quote Chart Rank Option Currency Glossary
Vigil Neuroscience, Inc. (VIGL)
3.13  -0.03 (-0.95%)    02-23 16:00
Open: 3.105
High: 3.2001
Volume: 28,522
Pre. Close: 3.16
Low: 3.07
Market Cap: 112(M)
Technical analysis
2024-02-23 4:40:14 PM
Short term     
Mid term     
Targets 6-month :  4.08 1-year :  4.77
Resists First :  3.5 Second :  4.08
Pivot price 3.01
Supports First :  2.9 Second :  2.52
MAs MA(5) :  3.08 MA(20) :  2.97
MA(100) :  4.38 MA(250) :  6.9
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  59.1 D(3) :  57.1
RSI RSI(14): 50.7
52-week High :  12.75 Low :  2.52
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ VIGL ] has closed below upper band by 34.4%. Bollinger Bands are 64.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 51 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 3.21 - 3.22 3.22 - 3.24
Low: 3.03 - 3.05 3.05 - 3.07
Close: 3.1 - 3.13 3.13 - 3.16
Company Description

Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts.

Headline News

Thu, 15 Feb 2024
Short Interest in Vigil Neuroscience, Inc. (NASDAQ:VIGL) Increases By 9.3% - MarketBeat

Wed, 07 Feb 2024
Vigil Neuroscience to Present at Guggenheim 6th Annual Biotechnology Conference - Yahoo Finance

Wed, 03 Jan 2024
Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 Milestones - Yahoo Finance

Mon, 20 Nov 2023
Vigil Neuroscience: Interim Data Sheds Light On Possible Accelerated Pathway (NASDAQ:VIGL) - Seeking Alpha

Fri, 17 Nov 2023
Why Is Rare Neurological Disease Focused Vigil Neuroscience (VIGL) Stock Trading Lower Today? - Vigil Neu - Benzinga

Fri, 17 Nov 2023
What is the Market's View on Vigil Neuroscience Inc (VIGL) Stock's Price and Volume Trends Friday? - InvestorsObserver

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 36 (M)
Shares Float 12 (M)
Held by Insiders 9.5 (%)
Held by Institutions 88 (%)
Shares Short 742 (K)
Shares Short P.Month 747 (K)
Stock Financials
EPS -2.02
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 3.78
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -28 %
Return on Equity (ttm) -46.2 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -2.33
Qtrly Earnings Growth 0 %
Operating Cash Flow -72 (M)
Levered Free Cash Flow -42 (M)
Stock Valuations
PE Ratio -1.55
PEG Ratio 0
Price to Book value 0.82
Price to Sales 0
Price to Cash Flow -1.57
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android